Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20447184 | 1.00 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL30059520 | 0.89 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL17155471 | 0.89 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL19901184 | 0.89 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL22244658 | 0.88 | AAK1 (0.78) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL17155390 | 0.86 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL19901192 | 0.86 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL30061130 | 0.86 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL28485569 | 0.85 | AAK1 (0.74) | AAK1ROCK2CYP3A4NR2C2CLK1 | |
| SCHEMBL19901188 | 0.83 | AAK1 (1.00) | AAK1ROCK2CYP3A4NR2C2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | claimed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | claimed |
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-06 | — | — | US | claimed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3356340-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | AAK1 1/4885ROCK2 680/4885CYP3A4 4285/4885 |
| US-10544120-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | AAK1 1/4885ROCK2 680/4885CYP3A4 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.